A new trading day began on Monday, with BioAtla Inc (NASDAQ: BCAB) stock price up 12.86% from the previous day of trading, before settling in for the closing price of $2.10. BCAB’s price has ranged from $1.14 to $4.02 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -56.91% over the last five years. Meanwhile, its annual earnings per share averaged 39.70%. With a float of $39.01 million, this company’s outstanding shares have now reached $48.08 million.
The firm has a total of 65 workers. Let’s measure their productivity. In terms of profitability, gross margin is 93.41%, operating margin of -678.7%, and the pretax margin is -560.61%.
BioAtla Inc (BCAB) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BioAtla Inc is 19.30%, while institutional ownership is 40.56%. The most recent insider transaction that took place on Dec 26 ’23, was worth 9,320. In this transaction Director of this company bought 4,000 shares at a rate of $2.33, taking the stock ownership to the 15,125 shares. Before that another transaction happened on Dec 20 ’23, when Company’s Chief Executive Officer bought 50,000 for $2.14, making the entire transaction worth $106,910. This insider now owns 1,439,283 shares in total.
BioAtla Inc (BCAB) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 39.70% per share during the next fiscal year.
BioAtla Inc (NASDAQ: BCAB) Trading Performance Indicators
Here are BioAtla Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.46 in one year’s time.
Technical Analysis of BioAtla Inc (BCAB)
Analysing the last 5-days average volume posted by the [BioAtla Inc, BCAB], we can find that recorded value of 1.3 million was better than the volume posted last year of 0.84 million. As of the previous 9 days, the stock’s Stochastic %D was 61.16%. Additionally, its Average True Range was 0.19.
During the past 100 days, BioAtla Inc’s (BCAB) raw stochastic average was set at 88.81%, which indicates a significant increase from 76.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.41% in the past 14 days, which was lower than the 98.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.91, while its 200-day Moving Average is $2.14. Now, the first resistance to watch is $2.55. This is followed by the second major resistance level at $2.74. The third major resistance level sits at $2.95. If the price goes on to break the first support level at $2.16, it is likely to go to the next support level at $1.95. Now, if the price goes above the second support level, the third support stands at $1.76.
BioAtla Inc (NASDAQ: BCAB) Key Stats
With a market capitalization of 108.37 million, the company has a total of 48,336K Shares Outstanding. Currently, annual sales are 0 K while annual income is -123,460 K. The company’s previous quarter sales were 0 K while its latest quarter income was -21,070 K.
